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Abstract: Previous studies have reported the upregulation of CCN proteins early after acute heart injury. The
aim of the present work was to evaluate the expression of the CCN1 and CCN2 proteins and their regulation by
angiotensin II in the atrial myocardium of a chronically failing heart. Male adult mice were subjected to ligation
of the left coronary artery to produce myocardial infarction (the MI group), and 16 of them were treated for 12
weeks with the AT1 receptor antagonist telmisartan (the MI-Tel group). Sham-operated mice served as controls.
The expression of proteins was evaluated by immunohistochemistry 12 weeks after the operation. In sham-
operated mice, stainings for CCN1 and CCN2 proteins were positive within atrial cardiomyocytes. CCN1-posi-
tive reaction revealed diffused cytoplasmic localization, while CCN2 was present mainly within the perinuclear
cytoplasm. CCN1 was upregulated in the MI group, while CCN2 remained at basal level. Telmisartan prevented
the upregulation of CCN1 and decreased CCN2 level. We compared the experimental data with the expression
of CCN1 and CCN2 proteins in human right atrial appendages. We found an inverse, but not significant, relation
between the level of either protein and the left ventricular ejection fraction. This suggests a similar atrial regu-
lation of CCN1 and CCN2 expression also in humans. We conclude that in the murine atria, CCN1 and CCN2
proteins are expressed constitutively. In chronic heart failure, CCN proteins tend to be upregulated, which may
be related to the action of angiotensin II. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 1, 99–103)
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Introduction
CCN1 (CYR61, cysteine-rich angiogenic inducer 61)
and CCN2 (CTGF, connective tissue growth factor)
are secreted, cysteine-rich proteins associated with the
extracellular matrix. Both of them modulate cellular
responses through interaction with integrins and reg-
ulate adhesion, migration, proliferation, differentia-
tion, survival of cells and apoptosis [1]. CCN proteins
are necessary in the process of cardiac development
and their expression in the ventricular myocardium
is upregulated after myocardial infarction or in chron-
ic heart failure [2, 3]. Basal CCN2 expression in the
atria of adult mice has been described as being high-
er than its physiological ventricular level, while the
expression of CCN1 in the atria has not been exam-
ined to date. Chronic impairment of the left ventric-
ular function results in hemodynamic overload to the
heart, including the atria. In addition, compromised
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cardiac function activates numerous neurohormonal
mechanisms. Both mechanical and neurohormonal in-
fluences promote remodeling of the myocardium and
worsen pumping performance of the heart [4, 5]. Atrial
remodeling present in the failing heart is the substrate
for supraventricular arrhythmias that may complicate
the course of disease and worsen the prognosis [6].
CCN proteins are regulated by mechanical stress,
as well as by angiotensin II or inflammatory cytokines
and growth factors, that are overexpressed in chronic
heart failure, and thus may be considered regulators
of the process of unfavorable atrial remodeling [3].
The aim of the present work was to analyze the
atrial expression of CCN1 and CCN2 proteins in the
mouse model of left ventricular failure induced by
experimental myocardial infarction and to evaluate
the impact of angiotensin type 1 receptor blockade
on the expression of these proteins.
Material and methods
Animal experimental procedure. Male C57BL/6J 14–16
week-old mice were used in the study. The animals were
subjected to coronary artery ligation to produce myocar-
dial infarction (n = 29) or to a sham operation (n = 10).
The operation was performed as described previously with
modifications [7]. Briefly, the animals were anesthetized with
isoflurane (AErrane, Baxter, USA). The trachea was intu-
bated via the oral cavity. Then the mice were put on a heat-
ed operating pad and ventilated with oxygen-enriched air
using a rodent respirator (Minivent, Harvard Apparatus,
USA). The chest was opened by a left-sided incision in the
fifth intercostal space, followed by opening of the pericar-
dial sac and exposure of the anterior wall of the heart. In
the ten sham-operated animals, after ten further minutes
the chest was closed in layers with reposition of the mus-
cles. In the remaining animals, the left coronary artery was
ligated just proximal to its main bifurcation, using a Prolene
7.0 suture with an atraumatic needle. The efficacy of myo-
cardial ischemia was assessed visually as pale discoloration
of the cardiac anterior wall. After closing of the chest wall,
animals were further ventilated with oxygen-rich air with-
out anesthetic until spontaneous breathing was evident (usu-
ally about two minutes). The mice were transferred to
a 27°C cage and left for one hour for recovery. Sixteen ani-
mals subjected to coronary artery ligation were for the next
12 weeks treated with telmisartan (Cat No. T8949, Sigma)
at a dose of 1 mg/kg/day in drinking water and this consti-
tuted the ‘MI-Tel group’, while the remaining mice after
myocardial infarction (the ‘MI group’) and those sham op-
erated were not subjected to further treatment. Animals
were sacrificed by cervical dislocation after 12 weeks fol-
lowing the operation. Left and right atria were instantly
harvested, rinsed in an ice-cold physiological saline solu-
tion and fixed in neutral buffered formalin.
Immunohistochemistry and microscopy. Formalin-fixed,
paraffin-embedded tissue blocks were sectioned into 5 μm
slices. After deparaffinization and rehydration, sections were
pretreated with proteinase K solution and then blocked with
10% donkey serum in PBS for one hour at room tempera-
ture. The endogenous peroxidase activity was blocked with
3% H2O2. The primary antibodies against CCN1 (H-78;
SantaCruz Biotechnology #sc-13100) and against CCN2
(L-20; SantaCruz Biotechnology #sc-14939) were applied in
a concentration of 1:100 dissolved in phosphate buffered
saline (PBS) for 90 minutes at room temperature. Then
slides were incubated with proper secondary antibodies (Se-
rotec Star54 over anti-CCN1 antibody and Serotec Star88
over anti-CCN2 antibody) conjugated with horseradish per-
oxidase at a concentration of 1:100 for one hour at room
temperature. Next, sections were rinsed with PBS and in-
cubated with DAB substrate (DAB Peroxidase Substrate
Kit, Vector Laboratories) for ten minutes. Nuclei were coun-
terstained with hematoxylin. Negative control of staining
was performed on the corresponding sections by omitting
the primary antibodies.
Protein level was assessed using the semi-quantitative
scale, where ‘+’ meant the lowest visible color reaction and
‘+ + + +’ the highest color reaction noted.
Estimation of CCN1 and CCN2 abundance in human right
atrial appendages. Specimens of the right atrial appendage
were harvested from 11 patients undergoing cardiac sur-
gery at the beginning of the operative procedure. Seven
patients were operated because of stable ischemic heart dis-
ease, one due to mitral valve insufficiency, and the remain-
ing three patients suffered from aortic valve disease. None
of the patients had been treated with inhibitor of angio-
tensin converting enzyme or AT1 receptor blocker for at
least one month before the operation. Tissue samples were
snap frozen in liquid nitrogen and stored at –80°C. Then
samples were homogenized in ice-cold RIPA buffer (Sig-
ma) with the addition of protease inhibitors (Protease In-
hibitor Cocktail for Mammalian Tissues, Sigma). Protein
concentration in each sample was determined using the
Bradford method (Bio-Rad) [8] and 25 μg of protein per
lane was loaded for electrophoresis. The CCN1 and CCN2
protein levels were estimated using the Western blot meth-
od as described previously [9] and their relative abundanc-
es were adjusted for b-actin (Sigma, #A5316). Ejection frac-
tion of the left ventricle, assessed by echocardiography ac-
cording to Simpson’s method, was used as a measure of left
ventricular systolic function.
Statistical analysis of the correlations between protein abun-
dance and ejection fraction was performed using a linear regres-
sion model with Statistica 8.0 PL software (StatSoft Polska).
All experimental procedures were carried out accord-
ing to the European Council Directive of 24 November 1986
(6/609/EEC) and were approved by the Local Ethics Com-
mittee in Bialystok.
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Results
In the atria of the sham-operated animals, the expres-
sion of both CCN1 and CCN2 proteins was present.
CCN1 showed a diffused cytoplasmatic pattern of
staining, but was non-uniform among different regions
of the atrial wall. A higher reaction was noted in the
subepicardial region of the muscle. CCN2 also showed
non-uniform expression within the atrial wall, with
regions of stronger and weaker reaction. In contrast
to the CCN1 staining, which was present in the whole
cytoplasm of the cell, CCN2 was localized mainly in
the cytoplasm in the direct proximity of the nucleus,
with a relatively low level in the subplasmalemmal
portion. In animals after myocardial infarction that
were not treated with telmisartan, staining for CCN1
revealed evident stronger color reaction, while CCN2
was only slightly increased with more diffused cyto-
plasmic staining. Telmisartan prevented upregulation
of CCN1 protein after infarction, and caused lower-
ing of CCN2 expression after infarction below the
level observed in the sham-operated animals. Table 1
presents the results of the semiquantitative analysis
of protein expression, and representative micropho-
tographs are presented in Figure 1. Evaluation of the
CCN1 and CCN2 proteins in human right atrial ap-
pendage specimens revealed an inverse relation be-
tween the abundance of CCN proteins and the left
ventricular ejection fraction, although the negative
correlation was not statistically significant (Figure 2).
Discussion
To the best of our knowledge, this is the first report
regarding the expression of CCN1 in the murine atria
in basal conditions and in chronic heart failure due
Figure 1. Representative immunohistochemical staining for detection of CCN1 and CCN2 proteins in the murine atria of
each group. Nuclei are counterstained with hematoxylin. Magnification × 200 (bar = 50 μm)
CCN1 CCN2
Sham
MI
Mi-Tel
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to myocardial infarction. In the human atria, eleva-
tion of atrial CCN1 has previously been described in
patients subjected to cardiopulmonary bypass graft-
ing [10]. Hilfiker-Kleiner et al. [3] described an ele-
vated level of this protein in the ventricular myocar-
dium early after myocardial infarction in mice. Up-
regulation of this protein was dependent on AT1 re-
ceptor stimulation, and protein kinase C or MEK/
/extracellular-regulated kinases inhibition were suffi-
cient to completely abolish CCN1 overexpression. The
same authors found CCN1 to be elevated in the ven-
tricular cardiomyocytes of patients with end-stage is-
chemic cardiomyopathy, but not in non-failing human
hearts. Our observations suggest upregulation of
CCN1 also in the atria of hearts with depressed sys-
tolic left ventricular function.
CCN1 is believed to exert a beneficial effect on
the myocardium. It promotes angiogenesis and pro-
tects cardiomyocytes from apoptosis after oxidative
injury [11]. Thus, elevation of CCN1 seems to be
a defensive mechanism against unfavorable influenc-
es. Our data is consistent with previous observations
regarding this protein [3, 10]. In the experimental
model, we found elevated expression of CCN1 that
seems to be at least partially related to stimulation of
the AT1 receptor.
CCN2 protein has been previously reported to be
expressed in the mouse as well as in human atria [12,
13]. In human atrial fibrillation, CCN2 is upregulat-
ed and influences the expression of connexin 43 or
N-cadherin in the atrial cells [13]. It has been previ-
ously postulated that CCN2 promotes fibroblast pro-
liferation and hypertrophy of cardiac myocytes in vit-
ro and in vivo [14, 15]. In the rat model of myocardial
infarction, CCN2 was shown to be involved in fibro-
sis and its expression increased in the viable myocar-
dium of the left ventricle late after the index event
[16]. In the ventricular myocardium of the human
failing heart, an increased CCN2 expression was ob-
served, which correlated well with the abundance of
the connective tissue within the ventricular cardiac
Table 1. Expression of the CCN1 and CCN2 proteins in the
atria of mice with chronic occlusion of the left coronary
artery
Protein Group
Sham MI MI-Tel
CCN1 + + + + + + + +
CCN2 + + + + + + + +
The level of protein was assessed visually and is expressed in
a semiquantitative scale from +, which was the minimal intensity of the
color reaction, to + + + +, which corresponded to maximal staining,
spanning most areas of the section
Figure 2. Relations between the abundance of CCN1 and
CCN2 protein in the human right atrium and the left
ventricular ejection fraction. Negative, but not statistically
significant, relation between levels of both proteins and
contractile performance of the left ventricle was observed.
Dashed line delineates 95% confidence interval. Respecti-
ve examples of representative Western blots are presented
above each diagram
muscle [17], and our data suggests that similar CCN2
upregulation is present in the atria. In the ventricular
myocardium, CCN2 was recently reported to exert
a protective role in ischemic cardiac failure. The mech-
anism proposed includes CCN2 dependent upregu-
lation of GRK5 activity, through which higher
b-adrenoreceptor desensitization may be achieved
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early after cardiac injury [18]. The role of angiotensin II
for CCN2 upregulation has been shown in vitro as well as
in vivo. The addition of angiotensin II to fibroblast cul-
ture elevated CCN2 mRNA and protein [19]. Pressure
overload of the left ventricle of the heart caused increased
expression of CCN2 protein, that was abolished by olme-
sartan — another AT1 receptor antagonist [20].
Although this protein may be responsible for in-
creased deposition of connective tissue also in the
atrial myocardium, there has been no direct investi-
gation targeting this specific issue to date. Our obser-
vations reveal that CCN2 is upregulated in the atria
of a failing heart, and that treatment with AT1 recep-
tor antagonist prevents this effect.
Conclusion
CCN1 and CCN2 proteins are constitutively expressed
in the cardiomyocytes of murine atria and are upreg-
ulated during chronic heart failure induced by per-
manent coronary artery ligation. Overexpression of
CCN1 and CCN2 proteins can be inhibited by AT1
receptor blockade, suggesting a role for angiotensin
II in the promotion of synthesis of both proteins in
the atria of a failing heart. The influence on atrial
CCN proteins may contribute to a beneficial effect of
angiotensin converting enzyme/angiotensin type 1
receptor antagonists in the prevention of atrial fibril-
lation in heart failure patients.
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